Šalis: Pietų Afrika
kalba: anglų
Šaltinis: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PURBAC® ADULT TABLETS PURBAC® DOUBLE STRENGTH TABLETS PURBAC® PAEDIATRIC SUSPENSION SCHEDULING STATUS: S4 PROPRIETARY NAME: (and dosage form) PURBAC ® ADULT TABLETS PURBAC ® DOUBLE STRENGTH TABLETS PURBAC ® PAEDIATRIC SUSPENSION COMPOSITION: 1. Each PURBAC ® ADULT tablet contains: Trimethoprim 80 mg Sulphamethoxazole 400 mg Preserved with Nipastat 0,025% m/m 2. Each PURBAC ® D.S. tablet contains: Trimethoprim 160 mg Sulphamethoxazole 800 mg Preserved with Nipastat 0,025% m/m 3. Each 5 mL of the PURBAC ® PAEDIATRIC suspension contains: Trimethoprim 40 mg Sulphamethoxazole 200 mg Alcohol 1,44% v/v Preserved with Nipastat 0,3% m/v PHARMACOLOGICAL CLASSIFICATION: A 20.2 Antimicrobial (Chemotherapeutic) Agents. (Other than antibiotics). PHARMACOLOGICAL ACTION: Co-trimoxazole exerts its bactericidal action by the sequential blockade of two enzymes intervening in the biosynthesis of folinic acid in the micro-organism. Co-trimoxazole is bactericidal at concentrations at which the active ingredients trimethoprim and sulphamethoxazole, are usually bacteriostatic. It is therefore often active against organisms resistant to one of the active ingredients thereby minimising the risk of bacterial resistance. INDICATIONS: Co-trimoxazole is effective against a wide range of Gram-positive and Gram-negative organisms. It is indicated for: 1. upper and lower respiratory tract infections e.g. acute and chronic bronchitis, bronchiectasis, tonsillitis, sinusitis and pharyngitis, otitis media, pneumonia and pneumocystis corinii pneumonitis (see Precautions). 2. renal and urinary tract infections e.g. pyelitis, pyelonephritis, urethritis, acute and chronic cystitis and cystopyelitis, including Perskaitykite visą dokumentą